Novogen: Phenoxodiol targets prostate cancer protein

By Elaine Rigoli

Tampa, Fla., Sept. 18 - Novogen Ltd.'s subsidiary, Marshall Edwards, Inc., said a new study demonstrates that the investigational drug phenoxodiol may be effective in the treatment of prostate cancer through its ability to target a protein that appears to be selective for prostate cancer cells.

Prostate cancer is one of the most serious and common types of cancer found in American men, killing more than 30,000 men every year, according to a news release.

Marshall Edwards, the Australian pharmaceutical company, said results suggest that phenoxodiol specifically targets a protein on prostate cancer cells known as tNOX 75 alpha, critical to the ability of the tumor cell to grow and to survive.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.